Natco Pharma Ltd has launched exemestane, a niche product which is used in the treatment of breast cancer under the brand name Xtane. Currently, it is available as a 25 mg tablets.

Exemestane is used in the treatment of breast cancer of post-menopausal women who respond to hormonal therapy and are hormone receptor positive. Being the first generic launch of exemestane, Xtane is priced at around 1/6th of the price of the innovator's brand, in line with the pricing policy of Natco.

Exemestane would offer a stable and economic option to hormone receptor positive patients who are expected to take this medicine for a minimum period of two years.